![]() Grade 3 to 4 TRAEs occurred in 12.9% of patients receiving nivolumab and 37.5% of those receiving nivolumab plus ipilimumab. Any-grade TRAEs were reported in 53.7% of patients in the nivolumab group and 68.8% of patients in the nivolumab plus ipilimumab group ( Table 3).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |